Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia.
Year: 2026
Type: article
Abstract: TO THE EDITOR: Covalent Bruton tyrosine kinase inhibitors (cBTKis) are commonly used targeted agents in early lines of therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); however, treatment following disease progression on cBTKis remains a challenge in clinical practice. Venetoclax is a B-cell lymphoma-2 inhibitor approved for CLL and SLL treatment, either as continuous monotherapy or as a fixed-treatment duration (FTD) regimen in combination with anti-CD20 antibodies (FTD Ven+anti-CD20; frontline, 12 months; relapsed/refractory, 24 months). Venetoclax has demonstrated durable responses and outcomes among patients with previous cBTKi exposure, both in clinical trials (eg, M14 032 and VENICE-1)6,7 and in real-world studies.
Source: UNC Libraries
DOI: 10.17615/63cv-5w58
Authors: Sinai, Wendy, Coyle, Michael, Coombs, Catherine C, Lansigan, Frederick, Pivneva, Irina, Ujjani, Chaitra, Martinez-Calle, Nicolas, Leslie, Lori A, Emechebe, Nnadozie, Kaddis, Nancy, Davids, Matthew S, Skarbnik, Alan P, Lamanna, Nicole, Hill, Brian T, Fakhri, Bita, Brown, Jennifer R, Choi, Yun, Shadman, Mazyar, Rhodes, Joanna M, Roeker, Lindsey E, Eyre, Toby A, Fleury, Isabelle, Jensen, Christopher E, Ghosh, Nilanjan, Schuster, Stephen J, Barr, Paul M, Chang, Andres, Tuncer, Hande H, Pearson, Laurie, Manzoor, Beenish S, Guerin, Annie, Thompson, Meghan C, Stephens, Deborah M
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7234838860
